ITV News' Natalia Jorquera visits the clinic that is looking to offer psychedelic drugs to patients as part of their mental health treatment
TheUKs first psychedelic assisted therapy clinic of its kindplans to open its doors to the public this autumn.
The clinic wants to combine psychedelic drugs - including ketamine and MDMA - with psychotherapy to treat patients with a wide range of mental health problems.
Dr Ben Sessa, Chief Medical Officer at Awakn Life Sciences in Bristol, believes psychedelic assisted psychotherapy will turn on its head the way traditional pharmacology is used in psychiatry.
We tend to treat psychiatric problems with maintenance therapy. You take an antidepressant every day, day in, day out for weeks, months, years, decades to mask your symptoms", Dr Sessa told ITV News.
"Now, the way we use psychedelic assisted psychotherapy is very different. You take the drug only one, two or three times alongside psychotherapy in order to get better and then not need to take daily drugs.
What are psychedelics?
Psychedelics are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perceptions, some can induce hallucinations.
The initial treatment offered when Awakn's clinic opens later this year will be ketamine-assisted psychotherapy for depression, anxiety, eating disorders, addiction and post-traumatic stress disorder (PTSD).Ketamine, is a Class A drug so it is illegal for recreational use, but approved for medical use and has been shown in several clinical trials to offer a brief, rapid antidepressant effect.Initially the clinic will offer patients will a nine week course of ketamine-assisted psychotherapy, which involves 11 visits to the clinic. On four of those occasions, a patient take ketamine assisted by their therapist, with the majority of the sessions will be 'talking therapy'.Although Dr Sessa hopes that one day their services will be available on the NHS, the therapy course will be for private patients, costing 6,000.
However, ketamine isnt the only psychedelic medicine that Awakn plans to offer. Dr Sessa believes in the next couple of years that MDMA and psilocybin known more commonly as magic mushrooms - will be approved for medical use, as both are in advanced stages of clinical trials in the UK.
Imperial College London launched the first psychedelic research centre in the world looking at the use of psychedelics in mental health care and have recently conducted trials into comparing psilocybin therapy with a conventional antidepressant drug.
Research leader, psychiatrist and neuroscientist Dr Robin Carhart-Harris told ITV News that their initial findings were very promising.
Results were quite consistent showing that the psilocybin therapy was really quite markedly better at reducing depressive symptoms. And actually more than that, it was also able to improve quality of life.
During the Imperial trial, all participants received talking therapy alongside taking either psilocybin or escitalopram the conventional antidepressant. Response rates in the psilocybin group averaged at70%, compared with 48% in the escitalopram group.
How does psilocybin work in the brain?
Like other psychedelic drugs is it works on a part of the brain or a system in the brain called serotonin system and serotonin. And the particular aspect of it that psychedelics work on is involved in something that we call plasticity, which means the ability of something to change, to be shaped or moulded", Dr Carhart-Harris said.
In Imperials brain imaging research they found that psilocybin increased plasticity and opened up new communication pathways.
As well as psilocybin, scientists also believe you can use MDMA to access a brain state where brain plasticity increases.
Earlier this year the first published study of advanced clinical trial using MDMA in the US was found to be highly effective in treating PTSD. Researchers at the Multidisciplinary Association for Psychedelic Studies (MAPS), found that after three MDMA sessions, 67% of participants no longer qualified for a PTSD diagnosis and88% experienced a reduction in symptoms.This data is why UK charity Supporting Wounded Veterans, backed by the head of the UK Armed Forces, General Sir Nick Carter, is calling for a UK trial.Gilly Norton, director of Supporting Wounded Veterans told ITV News that they see so many veterans with PTSD who are treatment resistant that they are are in need of a new therapy.
We see so many desperate veterans coming to us for help, most of them have been in treatment for about 10 years and not with great success, she said.
"There have been known new treatments in mental health now for 30 years and the medicine cabinet is completely bare.
The charity has been fundraising securing 300,000 from NHS England for UK clinical trials,but a gap of around 725,000 means that British veterans suffering from PTSD could face years of delays in receiving MDMA-assisted therapy, because regulatory approval is not possible without UK research.
For veteran Martin Wade, who came back from his tour in Afghanistan with PTSD, trials cant come soon enough.
My body's in a state of tension, I suffer with chronic pain. I am hypervigilant, I jump at even modest, unexpected sounds. I still have intrusive thoughts and nightmares and I just find daily living a struggle", he said.
Martin has had over 1,000 hours of therapy and has tried almost every method, including cognitive behavioural therapy (CBT) and eye movement desensitisation and reprocessing (EMDR). Nothing has provided him with much alleviation of his symptoms, so a treatment with such high success rate is what he's looking for.
When asked why he wanted to try this new therapy and what a life without PTSD would mean to him, Martin said: I would love to have a greater sense of inner wellbeing. So when I smile on the outside, I can feel it in the inside.
MDMA and psilocybin became Class A drugs under theMisuse of Drugs Act 1971, halting all research into them. Although this didnt stop people from taking them, it did create a stigma around them that they were only party drugs. It was only 15 years ago that psychedelic research was able to resume, but the substances do come with possible adverse effects - some psychedelic drug could cause extreme dissociation from reality, panic attacks and nausea.
The UKs Advisory Council on the Misuse of Drugs are currently considering barriers to legitimate research with controlled drugs, but told ITV News that there are no plans to reschedule MDMA under the Misuse of Drugs Regulations 2001.
However, that hasn't stopped millions of pounds being invested in the area - new startups are developing psychedelic initiatives and clinics around the world. The psychedelic market has been estimated to be worth around 5 billion by 2027.
The US state of Oregon have voted in favour of legalising psilocybin therapy and will begin treatments in 2023, so when do scientists think psychedelics could be a real alternative to conventional medicine?
Both Dr Sessa and Dr Carhart-Harris believe that MDMA and psilocybin will be licenced in the UK by 2025. At the moment, psychedelics still remain an experimental treatment and more research is needed in the area before they stand a chance of becoming a mainstream mental health therapy option in the UK.
- Study Finds 65% Of Americans With Mental Health Conditions Want Access To Psychedelics - Forbes - January 24th, 2022
- What are the potential risks of microdosing psychedelics? - Leafly - January 24th, 2022
- Trade To Black Podcast 20: Is the Selling In MSOS And Psychedelics Getting Overdone? A Frank Discussion - The Dales Report - January 24th, 2022
- Icebreakers with...MindMed CEO Rob Barrow - Morning Brew - January 24th, 2022
- Research in 60 Seconds: How Taking Psychedelics Can Be Therapeutic - UCF - January 24th, 2022
- TDRs Top 5 Psychedelic Developments For The Week Of January 17 - The Dales Report - January 24th, 2022
- The Psychedelics Series: The history and future of ketamine - The Cannabis Exchange - January 24th, 2022
- How 2021 became the year of psychedelics - and why 2022 is set to be even bigger - The Cannabis Exchange - January 24th, 2022
- Why Is Everyone Smoking Toad Venom? - What To Know About the Hallucinogenic Toad, DMT, Bufo - TownandCountrymag.com - January 24th, 2022
- Breaking Down Numinus Wellness Quarterly Results - The Dales Report - January 24th, 2022
- Ancient Latin American Empire Could Have Thrived Thanks to Psychedelic-Infused Beer - StreetInsider.com - January 24th, 2022
- Psychedelics can change humanity for the better. Its time ... - January 9th, 2022
- 'Microdosers' of LSD and magic mushrooms are wiser... - Daily Maverick - January 9th, 2022
- Core One Labs Now Also Working to Biosynthesize DMT and Receives License - Financial Post - January 9th, 2022
- NeonMind to Present at H.C. Wainwright Bioconnect Conference - Yahoo Finance - January 9th, 2022
- Magic mushroom companies are on the Nasdaq now. Thats a recipe for a bad trip - The Guardian - January 7th, 2022
- Psilocybin therapy options could expand in Hawaii | Hawai'i Public Radio - Hawaiipublicradio - January 7th, 2022
- From psychedelics to 'The Great Resignation' - wellness trends for 2022 - CapeTown ETC - January 7th, 2022
- Ketamine, Psilocybin and the Rise of Missouri Psychedelics - Riverfront Times - December 25th, 2021
- Animals That Eat Psychedelics And Enjoy The Trip - Benzinga - Benzinga - December 25th, 2021
- Bad Hug - The Cut - December 25th, 2021
- How Seeing God Might Be The Secret To The Most Cutting-Edge Mental Health Treatments - Forbes - December 25th, 2021
- Happy Holidays From The Dales Report Team - The Dales Report - December 25th, 2021
- GOP Lawmakers File Bills To Streamline Research Into Marijuana, Psychedelics And Other Schedule I Drugs - Marijuana Moment - December 22nd, 2021
- Meet Zappy Zapolin, The Psychedelic Concierge Who Turned Lamar Odom On To Ketamine - Forbes - December 22nd, 2021
- Numinus Wellness inc: Leading in the psychedelics race - Proactive Investors UK - December 22nd, 2021
- When Aldous Huxley Opened the Doors of Perception - The MIT Press Reader - December 22nd, 2021
- Kratom Attracts Investor Attention After Regulatory Win - Bloomberg - December 22nd, 2021
- Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so... - December 22nd, 2021
- Revenge travel and psychedelic retreats: The travel trends taking flight in 2022 - AsiaOne - December 22nd, 2021
- Cybin Awarded Notice of Allowance from US Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety... - December 15th, 2021
- TGA blocks bid to have MDMA, magic mushrooms used to treat mental health conditions - ABC News - December 15th, 2021
- PharmaTher Announces Positive Research Results for LSD Microneedle Patch - Yahoo Finance - December 15th, 2021
- MDMA could soon be used to treat PTSD according to physicians - Mixmag - December 15th, 2021
- MindMed Appoints Robert Barrow as Chief Executive Officer and Director - Yahoo Finance - December 15th, 2021
- MAPS and Wesana Health Resume Negotiations - GlobeNewswire - December 15th, 2021
- Sex, psychedelics and murderous impulses: Do we know too much about Will Smith? - The Independent - November 7th, 2021
- PharmaDrug commissions TIBI for advancing psychedelics program with analogue DMT formulation to cure eye diseases - Proactive Investors USA - November 7th, 2021
- I Have $1,000. Should I Invest In Cannabis, Crypto Or Psychedelics? - Benzinga - Benzinga - November 7th, 2021
- Psychedelics Could Be New Frontier in End-of-Life Care - Hospice News - November 5th, 2021
- Detroit just decriminalized psychedelics and magic mushrooms. Heres what that means - PBS NewsHour - November 5th, 2021
- Psychedelics linked to lower risk of heart disease and diabetes - Medical News Today - November 5th, 2021
- The people turning to psychedelics on their deathbeds - The Independent - November 5th, 2021
- Psychedelic Therapy Is Hyped, But Its Not Risk-Free: How Therapy Abuse Can Retraumatize Clients - Forbes - November 5th, 2021
- Defeating Gambling Addiction: New Study Looks To Defy The Odds With Psychedelics - Forbes - November 5th, 2021
- This Psychedelics Unicorn's Stock Is Up 50% In One MonthBeating Bitcoin, Ethereum And Dogecoin - Benzing - Benzinga - November 5th, 2021
- This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop - Benzinga - November 5th, 2021
- Biglaw Associate Is Advocating For Therapeutic Use Of Psychedelics And The Firm Is Backing Him Up - Above the Law - November 5th, 2021
- Easthampton is the fourth city in Mass. to vote to decriminalize psychedelics - WBUR - October 24th, 2021
- There Could Be a Curious Link Between Psychedelics And Improved Heart Health - ScienceAlert - October 24th, 2021
- How Atai Is Transforming The Landscape Of Mental Health Using Psychedelics (Part 2) - Forbes - October 24th, 2021
- A recent history of therapeutic psychedelics - Toronto Life - October 24th, 2021
- New Research Hints at a Link Between Psychedelics and Improved Heart Health - The Swaddle - October 24th, 2021
- Why Ketamine-Assisted Therapy Has Gone Mainstream - Forbes - October 24th, 2021
- Ketamine and psilocybin, better known as party drugs, showing promise for treatment of mood disorders - CTV News - October 24th, 2021
- Recent progress in psychedelic therapies - Lexology - October 24th, 2021
- Miracles and medication: The new science of psychedelic drugs - Stuff.co.nz - October 24th, 2021
- UAB researcher granted federal funding for psilocybin and smoking study - The Mix - October 24th, 2021
- Yale researchers using psychedelics to find new treatments for depression - WTNH.com - September 17th, 2021
- Want Quick Exposure To The Psychedelics Sector? Check Out This New Active ETF - Benzinga - Benzinga - September 17th, 2021
- 5 things to know about the Ann Arbor psychedelic shroom fest - MLive.com - September 17th, 2021
- A Look At Psychedelics Stock PharmaTher And Its Recent Bull Run - Benzinga - Benzinga - September 17th, 2021
- Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) -... - September 17th, 2021
- Psychedelics research and public education elevated by multiple gifts - UC Berkeley - September 16th, 2021
- Pain Awareness Month: Psychable Educates Patients on Transformative Power of Using Psychedelics as Medicine for Pain Treatment, Management and Healing... - September 16th, 2021
- $80 Million Granted to Research Psychedelic Properties of Ingesting Toad Venom - Newsweek - September 16th, 2021
- Psychedelic Use on the Rise As Gen Z Seeks To Enhance Connectedness - VICE UK - September 16th, 2021
- Phyto Partners Cannabis VC on Why He's Investing in Psychedelics - Business Insider - September 16th, 2021
- Detroit Voters Will Decide On Psychedelics Decriminalization Ballot Measure In November - Marijuana Moment - September 16th, 2021
- Seattle bid to decriminalize psychedelics could have profound effect on treating addiction - MyNorthwest.com - September 16th, 2021
- Post-9/11 vets go to Mexico to treat trauma with psychedelic - The San Diego Union-Tribune - September 16th, 2021
- Lobe Sciences to Participate at the Advances in Me... | INN - Investing News Network - September 16th, 2021
- Seattle is now in the process of legalizing psychedelics, heres what to know - Curiocity - September 16th, 2021
- World Suicide Prevention Day: Suicide Remains a Leading Global Cause of Death; Communities Across the World Seek Expanded Use of Psychedelics as... - September 16th, 2021
- Psilocybin Transdermal Patches Could Be The Next Big Thing In Psychedelics - Forbes - September 1st, 2021
- Psychedelics are getting closer to approval, but the market may not be ready - FierceBiotech - August 22nd, 2021
- At-Home Genetic Testing Cant Tell You If Youre Going to Have a Bad Trip - VICE - August 22nd, 2021
- Past, Present & Future of Psychedelic-Assisted Therapy: A New Dawn for Mental Health and Neuroscience - cmc.edu - August 22nd, 2021
- Researchers breaking away from the central dogma of depression - STAT - STAT - August 22nd, 2021
- When did humans start experimenting with alcohol and drugs? - EL PAS in English - August 22nd, 2021